



EC grants approval to Sanofi's SARCLISA SC in combination with standard-of-care regimens for the treatment of patients with multiple myeloma

(EU, Approval)



TearSolutions' LACRIPEP received Orphan Drug and Fast Track designations from the FDA to treat neurotrophic keratitis

(FDA, Orphan Drug, Fast Track)



FDA grants Fast Track designation to Merakris Therapeutics' MTX-001 that treats venous leg ulcers

(FDA, Fast Track)



FDA provides Fast Track designation to Verastem Oncology's VS-7375 for the treatment of adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic NSCLC

(FDA, Fast Track)



(FDA, Fast Track)



FDA gives Fast Track designation to Terremoto's TER-2013 to treat patients with locally advanced, unresectable or metastatic HR+/HER2- breast cancer

(FDA, Fast Track)



Nouscom's NOUS-209 gets FDA Fast Track designation for the prevention of Lynch syndrome associated cancers with MMR mutations

(FDA, NDA)



FDA accepts Genentech's NDA for giredestrant under Priority Review to treat adults with stage 1, 2 and 3 (ER)-positive, (HER2)-negative breast cancer

(Acquisition)



UCB acquires Neurona Therapeutics, marking a strategic expansion into regenerative medicine and advanced therapies along with adding rezanecel to its epilepsy portfolio



 **Hanmi**

Hanmi enters into a license agreement with Eli Lilly to develop, manufacture and commercialize sonefpeglutide for short bowel syndrome

(Collaboration)

 **百奥泰**
BIO-THERA

Bio-Thera's BAT2506 demonstrated equivalent efficacy, comparable safety and immunogenicity to SIMPONI, with an ACR20 response rate of 79.26% at 14 weeks in the Phase 3 trial

(Phase 3, Results)

 **AstraZeneca**

AstraZeneca's Phase 3 SERENA-6 trial evaluating camizestrant plus a (CDK) 4/6 inhibitor met its primary and secondary endpoints along with reducing the risk of second disease progression or death by 37%

(Phase 3, Results)

 **AstraZeneca**

Phase 3 I CAN trial experimenting AstraZeneca's ULTOMIRIS showed clinically meaningful reduction in proteinuria compared to placebo at week 34 in adults with IgA nephropathy

(Phase 3, Results)

